Imricor Med and Philips launch commercial iMR lab solution

• Global collaboration advances MR-guided cardiac interventions
• Integrated, purpose-built solution
• Supports adoption of iMR-guided cardiac care
• Scalable commercial platform

Imricor Medical Systems (ASX: IMR) has launched a new Interventional MR (iMR) lab solution in collaboration with Dutch multinational health technology company Royal Philips.

Listen to the HotCopper podcast for in-depth discussions and insights on all the biggest headlines from throughout the week. On Spotify, Apple, and more.

The combined iMR lab solution brings together Philips’ high-performance 1.5 Tesla (1.5T) MRI platform and interventional workflow capabilities with Imricor’s portfolio of MR-compatible systems and consumables.

Imricor chair, president and CEO, Steve Wedan, said the first commercially available configuration is designed to enable iMR-guided workflows for cardiac interventions, including cardiac electrophysiology procedures.

“With interventional MR, the idea is not to move procedures into diagnostic MRI suites, but rather to bring MR imaging into the procedure room. Our collaboration with Philips has always been driven by this shared vision, and with our combined iMR lab solution, that vision becomes a reality today,” Mr Wedan said.

“Pairing Philips’ world-class 1.5T MR platform with Imricor’s exclusive portfolio of advanced iMR systems and interventional tools creates the world’s first state-of-the-art high- performance iMR lab solution. We believe the future is about advanced image guidance for therapies and interventions, and the future is here now.”

The launch follows the Philips third party declaration of compatibility and it represents a significant milestone in the longstanding Philips-Imricor partnership, advancing since 2012 from joint technology development to the commercial launch of a purpose-built iMR lab solution.

“Our ambition is not only to advance what clinicians can see with MRI, but also what they can do with it,” Philips business leader, Magnetic Resonance, Ioannis Panagiotelis, said.

“Philips has a long history of helping clinicians perform image-guided procedures with confidence, and we believe MRI can play an even greater role in providing care. With this new iMR lab solution, enabled through our collaboration with Imricor, we’re expanding the role of cardiac MRI from diagnosis into the treatment environment.

“Cardiac electrophysiology is just the beginning. This iMR lab solution represents an important step in Philips’ strategy to advance MRI across the care continuum, creating a platform that can expand into additional clinical areas while helping clinicians deliver the best possible care for their patients.”

Interventional magnetic resonance imaging (iMRI) is the use of MRI scanner technology to guide minimally invasive surgical and diagnostic procedures in real time.

IMR was up 4.15% to $2.01. Mkt cap $692.0M.

Join the discussion: See what HotCopper users are saying about Imricor Medical Systems be part of the conversations that move the markets.

The material provided in this article is for information only and should not be treated as investment advice. Viewers are encouraged to conduct their own research and consult with a certified financial advisor before making any investment decisions. For full disclaimer information, please click here.